商標ウォッチ

公開日2025-11-19
公報種別公開国際商標公報
国際登録番号1876362
国際登録日2025-04-08
区分第5類(薬剤)
商品役務Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutic agents; biopharmaceuticals; medicines; drugs; vaccines; gene therapy systems used to express therapeutic proteins in vivo for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases 全 89 件を表示, aging-related pathologies, genetic diseases, and blood disorders; gene therapy products; gene therapy preparations; in vivo nucleic acid for medical purposes; in vivo DNA technologies, RNA technologies, and mRNA technologies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; lipid nanoparticles for medicinal use; binding moiety decorated lipid nanoparticles for medicinal use; lipid nanoparticles for durable cell reprogramming or cell engineering; binding moiety decorated lipid nanoparticles for durable cell reprogramming or cell engineering; cell engineering platforms for modifying and manipulating cells for medical purposes; biotechnological cell engineering platforms for treatment of human diseases, disorders and conditions; biotechnological technology platforms for developing and engineering therapeutic cells for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biotechnological in vivo cell engineering platforms for developing and engineering therapeutic cells, transient gene therapy, and durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biotechnological transient in vivo cell engineering platforms for durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biotechnological technology platforms for transfection, namely, binding moiety decorated lipid nanoparticles for genetic engineering; reagents for transfection; reagents for transfection in vivo; reagents for transfection, namely, binding moiety decorated lipid nanoparticles; biotechnological technology platforms for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; biotechnological technology platforms for delivery of a nucleic acid payload; biotechnological technology platforms for delivery of a negatively charged payload; biologics delivery systems comprised of lipids, nucleic acids and proteins; biologics delivery platforms comprised of lipids, nucleic acids and proteins; reagents for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; cell engineering platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, mRNA, and antibodies or antigen binding portions thereof; biological technology platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, nucleic acid, DNA, RNA, mRNA, and antibodies or antigen binding portions thereof, for the treatment and prevention of treatment of human diseases, disorders and conditions; chemical reagents for medical uses; clinical medical reagents; reagents for medical use; biological reagents for medical use; binding moiety decorated lipid nanoparticles.
基礎出願番号98795718
基礎出願日2024-10-10
基礎出願国US
出願人CAPSTAN THERAPEUTICS, INC.
OCRテキストCELLSEEKEK
OCRについて

関連商標